Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice.
Vaccines have been recently developed to treat various diseases such as cancer, rheumatoid arthritis and Alzheimer's disease in addition to infectious diseases. However, before use in the clinical setting, vaccines targeting self-antigens must be demonstrated to be effective and safe, evoking a...
Guardado en:
Autores principales: | Futoshi Nakagami, Hiroshi Koriyama, Hironori Nakagami, Mariana Kiomy Osako, Munehisa Shimamura, Mariko Kyutoku, Takashi Miyake, Tomohiro Katsuya, Hiromi Rakugi, Ryuichi Morishita |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cdcd8e024d3e4ac6869e79224ddf17f6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice
por: Shota Yoshida, et al.
Publicado: (2020) -
Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey
por: Munehisa Shimamura, et al.
Publicado: (2021) -
RAGE ligands stimulate angiotensin II type I receptor (AT1) via RAGE/AT1 complex on the cell membrane
por: Serina Yokoyama, et al.
Publicado: (2021) -
Hepatocyte Growth Factor Prevented High-Fat Diet-Induced Obesity and Improved Insulin Resistance in Mice
por: Jun Muratsu, et al.
Publicado: (2017) -
Essential role for miR-196a in brown adipogenesis of white fat progenitor cells.
por: Masaki Mori, et al.
Publicado: (2012)